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Summary  
Background: Circulating adiponectin concentrations were lower in ponies with a history of 
endocrinopathic laminitis and in non-laminitic ponies that subsequently developed laminitis. The 
assays used in these studies have been discontinued or are no longer valid. 
 
Objectives: i) To determine the validity of immunoturbidimetric (IT) and enzyme 
linkedimmunosorbent (ELISA) assays for equine total and high molecular weight (HMW) 
[adiponectin] measurement and ii) to investigate the association between [adiponectin] measured 
using these assays and endocrinopathic laminitis.   
 
Study design: Method validation and cohort study. 
 
Methods: Accuracy and precision of IT and ELISA assays for measuring total (TAC) and HMW 
(HMWAC) [adiponectin] were determined. Using the IT assay, the effects of anti-coagulant and 
storage temperature were assessed, TAC was measured in previously laminitic (PL) and never 
laminitic (NL) ponies (n = 6/group). Comparison with a previously validated radioimmunoassay was 
made in NL ponies (n = 223). Association between TAC and subsequent laminitis development in NL 
ponies was investigated using univariable logistic regression and ROC curve analysis.  
 
Results: The IT assay was precise and demonstrated good agreement with the previously validated 
radioimmunoassay. TAC was significantly (p<0.01) lower in PL (mean ± s.d. 8.9 ± 2.9 g/ml) 
compared to NL (24.2 ± 11.8 g/ml) ponies and in NL ponies that developed laminitis within 12 
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months (median 4.8 g/ml; IQR 2.65-13.4 g/ml) compared to those that remained non-laminitic 
(19.9 g/ml; 9.95-31.5 g/ml). TAC was significantly (p = 0.01) associated with laminitis occurrence 
within 12 months. Use of the area under the ROC curve to distinguish animals that did and did not 
develop laminitis showed good accuracy (0.76). None of the ELISA methods validated satisfactorily.  

Main limitations: Laminitis risk is based on data from ponies in one region.  
 
Conclusions: The IT method is suitable for measurement of equine TAC. TAC is lower in ponies with 
previous or future laminitis. The ELISA methods are not suitable for measurement of equine HMWAC 
or TAC.  
 
Introduction 
Equine metabolic syndrome (EMS) is a collection of clinical abnormalities including insulin 
dysregulation (ID), dyslipidaemia and altered circulating adipokine concentrations, with or without 
obesity, associated with increased laminitis risk  [1]. Whilst there are multiple circulating adipokines, 
leptin and adiponectin have been evaluated in horses in relation to the pathogenesis of, and as 
diagnostic markers for, EMS. Whilst leptin concentrations were strongly associated with obesity, 
they were not useful for identifying previously laminitic animals [2]. Contrastingly, concentrations of 
the anti-inflammatory  [3] and insulin-sensitising adipokine adiponectin [4] decreased significantly 
when horses were fed a carbohydrate-rich diet sufficient to induce obesity and ID, but not when fed 
a high fat diet that induced obesity alone [5]. Additionally, circulating adiponectin concentrations 
were lower in previously laminitic compared to never laminitic ponies [2,6]. Finally, in non-laminitic 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
ponies, hypoadiponectinaemia was an independent predictor of future laminitis development in a 
multivariable model of laminitis risk [7]. 
 
Investigation of equine adiponectin production has been limited. In other species, adiponectin is 
synthesised in white adipose tissue as monomers and secreted into the peripheral circulation where 
it circulates as trimers, low molecular weight hexamers and high molecular weight (HMW) multimers 
[8]. In human type 2 diabetes, impaired multimerisation may occur before an overall reduction in 
adiponectin secretion [9]. Thus, concentrations of  HMW adiponectin (HMWAC) decrease before 
reductions in total adiponectin concentration (TAC) and HMWAC may be a more sensitive marker of 
metabolic disease than TAC; although the evidence is conflicting [10,11]. The HMWA complex may 
also be more biologically active than lower molecular weight forms due to greater receptor affinity 
[8]. The relative merits of measuring different adiponectin fractions in equids requires further study. 
Both TAC and HMWAC have been associated with obesity [12] and are negatively correlated with 
insulin concentrations [13]. 
 
Previous equine studies used an enzyme linked immunosorbent assay (ELISA) to measure HMWAC 
[12] and a  radioimmunoassay (RIA) [7,14]  to measure TAC. Production of the validated ELISA has 
been discontinued and the antibody used in the RIA has been altered adversely affecting the validity 
of the assay in equids (E Knowles, unpublished data). The objectives of this study were i) to 
determine whether a latex enhanced immunoturbidimetric (IT) assay used for measurement of 
human TAC or ELISA methods for measuring TAC or HMWAC provide reliable means of measuring 
equine adiponectin concentrations and ii) to determine whether adiponectin concentrations 
measured using reliable assays provide a diagnostic marker for laminitis risk.  
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Materials and Methods 
Part 1. Assay Validation 
The study was performed using residual serum and plasma from samples submitted to a commercial 
laboratory for the investigation of EMS or routine health screening (IT assay). In addition, serum and 
plasma samples collected under Home Office project licence (PED1AA054) and approved by the 
Royal Veterinary College Ethics and Welfare Committee from never laminitic (NL; n = 6; all mares; 
aged 19.8 ± 4.8 years; native breed ponies) ponies (HMWAC and TAC ELISA) were used. All samples 
were collected by jugular venepuncture into vacutainer tubes containing clot activator (serum 
samples), ethylenediaminetetraacetic acid (EDTA) and heparin vacutainers, allowed to clot (serum 
samples only), separated by centrifugation, aliquoted and stored at -20°C (commercial samples) or -
80°C (research samples) until analysed. Two different sets of samples were used due to ease of 
availability. 
 
The assays to be validated were 1) an IT assaya for measurement of TAC; 2) human (Mercodia 
Adiponectin ELISA [10-1193-01]b) and equine (Nori® Equine Adiponectin ELISA kit [GR106557]c) 
specific ELISA methods for measurement of TAC; and 3) an equine specific ELISA (Horse High 
molecular weight adiponectin ELISA kit [E10A0530]d) or measurement of HMWAC.  
 
Assay methods 
The IT assay for measurement of TAC was performed using commercial clinical chemistry analyser 
(Biolise) according to the manufacturers’ instructions. The three ELISAs were similarly all performed 
according to the manufacturer’s instructions and the optical density read at 450 nm using a plate 
reader (Tecan infinite pro 200 plate reader using Magellan 7 softwaref). A commercial control kit 
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(Mercodia Obesity Control Kit [10-1241-01]b) was used in conjunction with the human ELISA for 
measurement of TAC as an internal quality control.  
 
Assay precision  
For the IT assay, serum samples of known adiponectin concentration were pooled into high and low 
pool samples (n = 3 samples/group), respectively. Each pooled sample was analysed three times 
within a run on each of three consecutive days. Similarly made pooled heparin plasma samples were 
assayed three times within each of two assays run on consecutive days for the equine specific ELISA 
for HMWAC. Aliquots that were analysed on subsequent days were kept stored at -20°C. Coefficients 
of variation were determined for intra-day/assay and inter-day/assay variability for each test assay. 
No signal was obtained from the equine or human specific ELISAs for measuring TAC using serum or 
plasma.  
 
Dilutional parallelism 
High pool samples were serially diluted from 1:2 up to 1:32 with low pool samples (IT assay for TAC) 
or phosphate buffered salineg (equine specific ELISA for HMWAC) as per the manufacturers’ 
recommendations to produce samples that spanned the working range of each assay. Samples were 
then analysed in duplicate within the same assay run/kit and measured concentrations were 
compared to calculated concentrations. 
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Spiked recovery 
Low pool samples were spiked with the high calibrator (IT assay for TAC) or highest standard (equine 
specific ELISA for HMWAC) for the assay to produce five samples within the working range of each 
assay.  These samples were analysed in duplicate within the same assay run/kit and the mean of 
each pair compared to expected concentrations. 
 
Effect of temperature, time and anti-coagulant 
For the IT assay, EDTA plasma, heparin plasma and serum samples (n = 5 for each) were separated 
into aliquots and individual aliquots were analysed immediately (T0) and then either stored at -20°C 
in a domestic freezer or at 4°C, 23°C or 30°C in temperature-controlled cabinets. Samples were 
analysed after 24, 48 and 72 hours of storage. Data were expressed as a percentage of the T0 serum 
sample.  
 
Part 2. TAC as a diagnostic marker for laminitis 
 
TAC in previously laminitic and never laminitic ponies 
Blood samples were collected by jugular venepuncture into vacutainersh containing clot activator 
from previously laminitic (PL; n = 6; 5 mares, one gelding; aged 16.7 ± 2.9 years [mean ± s.d.]; native 
breed ponies) and never laminitic (NL; n = 6; all mares; aged 19.8 ± 4.8 years; native breed ponies) 
ponies with no other clinical signs consistent with pituitary pars intermedia dysfunction and plasma 
ACTH concentrations within the seasonally adjusted reference range. Vacutainers were incubated at 
37°C in a water bath for 30 minutes, centrifuged and the serum separated and frozen at -80°C until 
analysis.   
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TAC as a marker of future laminitis risk and comparison with previously validated radioimmunoassay 
 
TAC were measured using the IT assay in stored serum samples collected from a cohort of NL ponies 
(n = 223; one sample per animal) ≥7 years old that had been the subject of a previous study  [7]. As 
part of the previous study, follow-up was obtained from owners 12 months after samples were 
collected to determine which animals had subsequently developed laminitis and TAC was measured 
using a human radioimmunoassay (RIA)i that is no longer valid for equine samples due to an 
antibody alteration. In this previous study, TAC was associated with future laminitis in a 
multivariable analysis [7]. 
 
Data analysis 
Data were analysed using statistical and graphing softwarej,k. The normality of continuous data was 
assessed using the Shapiro-Wilk normality test. The effect of anti-coagulant was determined using a 
one-way repeated measures ANOVA with Tukey’s multiple comparisons test. The effects of storage 
temperature and time were determined by visual inspection of the data plotted against time using 
the pre-determined criteria that ≤10% degradation was clinically acceptable and veterinarians are 
unlikely to be able to freeze samples immediately, but can usually maintain samples at 4-23°C. 
 
Total adiponectin concentration (TAC) in PL and NL ponies were compared using an unpaired t test 
and between NL ponies that developed laminitis and those that remained non laminitic using a 
Mann Whitney U test.  The relationship between TAC as measured by the IT method and the 
previously validated RIA method [6] was examined by performing linear regression, creating ratio 
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(IT:RIA) Bland-Altman plots to show the limits of agreement between the methods and by calculating 
the intraclass correlation coefficient (ICC) whereby an ICC of <0.40 is considered poor, 0.40 - 0.59 
fair, 0.60 - 0.74 good and ≥0.75 excellent. Univariable logistic regression was used to assess whether 
TAC was associated with the outcome (namely laminitic after 12 months or not). A ROC curve was 
constructed for TAC and the accuracy of the test to separate animals into those which did or did not 
subsequently develop laminitis was determined by calculating the area under the curve (AUC) 
whereby an area of 0.90-1 is excellent, 0.80-0.89 good, 0.70-0.79 fair, 0.60-0.69 poor and 0.50-0.59 
fail [29]. In addition, the co-ordinates of the ROC curve were then used to determine the cut-off 
value that maximised specificity and sensitivity and the corresponding positive (PPV) and negative 
predictive values (NPV) using this cut-off value were calculated. Significance was accepted at p≤0.05. 
 
Results 
Part 1: Assay Validation 
Assay precision  
Mean (± s.d.) intra-assay (within day) and inter-assay (between day) coefficients of variation for the 
IT assay for TAC were calculated as 1.02 ± 0.15% and 1.87 ± 0.93%, respectively. The mean (± s.d.) 
intra-assay and inter-assay coefficients of variation for the equine specific ELISA for HMWAC were 
7.35 ± 1.6% and 89.1 ± 56.8%, respectively.  
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Dilutional parallelism  
The IT assay for TAC demonstrated acceptable dilutional parallelism; mean ± s.d. measured 
concentration was 107 ± 5.83% of the expected concentration. However, the equine specific ELISA 
for HMWAC did not; mean ± s.d. measured concentration was 2210.8 ± 1847% of the expected 
concentration.  
 
Spiked recovery 
Percentage recovery from spiked samples measured using the IT assay for TAC was acceptable; 
mean ± s.d. recovery of 111 ± 2%. However, the recovery from spiked samples using the equine 
specific ELISA for HMWAC was not acceptable; mean ± s.d. recovery of 21.2 ± 11.9%. 
 
Effect of anti-coagulant and storage temperature and time 
TAC at T0 measured using the IT assay in samples collected into EDTA (mean ± s.d. 10.5 ± 3.6 g/ml) 
was significantly lower than TAC in serum samples (p = 0.009; 11.1 ± 4.0g/ml) or in samples 
collected into heparin (p = 0.003; 11.1 ± 3.7g/ml). TAC in samples stored at different temperatures 
for up to 72 hours measured using the IT assay are shown in Table 1. On the basis of visual 
inspection of graphs, EDTA was unsuitable as an anti-coagulant if the sample was not kept frozen (-
20°C) or chilled (4°C); heparinised plasma and serum samples gave similar results when stored 
between -20 and 23°C; heparinised plasma and serum samples should be analysed within 24 hours if 
stored at 23°C; and no sample type was suitable if the sample was stored at 30°C. 
  
Part 2. TAC as a diagnostic marker for laminitis and comparison with a previously validated 
radioimmunoassay  
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TAC in previously laminitic and never laminitic ponies 
 
Mean ± s.d. TAC in NL ponies (24.17 ± 11.83 µg/ml) was significantly (p = 0.01) greater than in PL 
ponies (8.95 ± 2.94 µg/ml).  
 
TAC as a marker of future laminitis risk and comparison with previously validated radioimmunoassay 
(RIA) 
Linear regression indicated that TAC measured using the IT assay (g/ml) = 0.1249 x RIA + 1.78 (r2 = 
0.48; Fig 1). The ICC was 0.54 (0.51, 0.59) consistent with fair agreement between the methods and 
Bland-Altman analysis revealed a mean bias (limits of agreement) methods of 4.4 (1.1, 7.9) in the 
ratio of IT:RIA (Fig 1). 
 
As previously reported [7], nine of the 223 ponies developed laminitis within 12 months of sample 
collection. Median (IQR) TAC measured using IT assay in ponies that remained non-laminitic (n = 
214; 19.9 µg/ml; 9.95, 31.53) was significantly (p<0.001) greater than in ponies that developed 
laminitis (n = 9; 4.8 µg/ml; 2.65, 13.4). TAC was significantly (p = 0.04) associated with the outcome 
(namely laminitic after 12 months or not). The area (95% confidence intervals) under the ROC curve 
was 0.762 (0.64, 0.88; p = 0.001), which is considered good.  From the ROC curve analysis, an 
optimal cut-off of 24.1 g/ml was determined, which generated sensitivity and specificity values of 
89% and 60% respectively. The odds ratio (OR) (95% confidence interval) was 0.91 (0.87, 0.97) i.e. a 
pony with a value above this cut-off is 9% less likely to develop laminitis. This is reflected in the high 
negative predictive value (NPV) for development of laminitis of 98.7%. However, the positive 
predictive value (PPV) of 11.0% was extremely low using the optimal cut-off of 24.1 µg/ml and did 
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not increase even if the cut-off was reduced as low as 11 µg/ml reflecting the overall low prevalence 
of laminitis in this cohort.  
 
Discussion 
This study has demonstrated that a human IT assay for TAC is suitable for the measurement of 
equine TAC in serum and heparinised plasma stored between -20 and 23°C for up to 72 hours and in 
EDTA plasma for up to 48 hours provided it is stored at 4°C or below.  This assay can be performed 
quickly and reliably using commercial biochemistry analysers that are available in many equine 
hospitals and by operators with limited experience. In contrast, the accuracy and precision of ELISA 
methods evaluated herein for the measurement of equine HMWAC or TAC was unacceptable and 
their use cannot be recommended.  It should be acknowledged, however, that there may be other 
ELISAs available for measurement of either TAC or HMWAC in equine samples that were not tested 
in this study. 
 
In stored samples, TAC decreased after 24 hours at higher temperatures; however, in frozen or 
chilled samples concentrations remained stable. Therefore, whilst the analysis of chilled or frozen 
serum is preferred, the use of chilled or frozen plasma is acceptable. Whilst TAC was significantly 
lower in samples collected into EDTA compared to serum samples and samples collected into 
heparin, the magnitude of this difference is unlikely to be clinically relevant. Investigations of the 
stability of adiponectin in whole blood were not performed, so samples should be separated before 
shipping to a postal laboratory.  
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TAC measured using the IT assay correlated with, but were higher than those determined using the 
RIA method that has been validated and used in previous studies [6,7]. Results generated in the 
current study are, however, consistent with TAC in other species such as 5 to 30 µg/ml in humans, 9 
to 17.4 µg/ml in mice, and 0.052 to 33.8 µg/ml in dogs [15,16]. It has been suggested previously that 
the RIA method may have low affinity for equine adiponectin [12] and if this is true then the IT assay 
may provide a more accurate estimate of circulating TAC. Further investigations would be required 
but are unlikely to be possible, as the antibodies used in the RIA have been changed since it was 
validated such that it no longer produces acceptable results.  
 
 In agreement with previous studies, low TAC was associated with previous laminitis or future 
laminitis [2,6,7]. However, these conclusions are drawn on a population basis and its value as a 
means of predicting laminitis in an individual animal should be considered carefully. Whilst a cut-off 
value of 24 g/ml maximised diagnostic accuracy for predicting the future development of laminitis, 
due to the low prevalence of laminitis within the population, the positive predictive value of the test 
was only 11% i.e. for every 100 horses that were identified as having a low adiponectin 
concentration only 11 would go on to develop laminitis. By contrast, the negative predictive value 
was extremely high (99%). Therefore, the result in an individual animal should be interpreted 
accordingly with the emphasis on a high value being consistent with an extremely low risk of 
developing laminitis without over-interpretation of a low value. The positive predictive value of the 
test for laminitis would be expected to improve if it were used only in ponies selected based on 
clinical signs and phenotype rather than being used to screen a population; further investigations 
are required. 
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Whilst measurement of TAC is likely to be helpful in individual animals suspected of having 
metabolic disease, additional testing of insulin dysregulation should be considered to determine a 
more complete picture of metabolic dysfunction and laminitis risk. Many horses with some of the 
metabolic alterations consistent with EMS do not develop laminitis and further research is required 
to determine whether this relates to the severity of the underlying metabolic disease or the 
interaction between metabolic dysfunction and other factors. There is a far greater body of evidence 
to support the use of assessments of insulin dysregulation in equids with EMS or pituitary pars 
intermedia dysfunction to determine laminitis risk and measurement of TAC should be considered 
an adjunct rather than an alternative. In addition, it should be acknowledged that in the previous 
study evaluating multiple risk factors, combining the individual significant risk factors such as basal 
insulin concentration and TAC did not increase the predictive power [7].   
 
The reason for the apparent association between lower adiponectin concentrations and laminitis is 
unknown and further studies are required. Adiponectin has been shown in other species to open 
smooth muscle potassium channels and to increase vascular expression of both endothelial nitric 
oxide synthase and prostacyclin synthase all of which promote vasodilation [17,18] and this may 
provide a means by which adiponectin is protective against laminitis. In man, adiponectin in 
association with insulin stimulates insulin receptors and IGF-1 receptors [19] so reductions in 
circulating adiponectin concentrations may increase the risk of laminitis that occurs in association 
with hyperinsulinaemia. Alternatively, adiponectin may simply be a marker of the metabolic 
derangements that lead to laminitis and may have no direct role in the pathogenesis of laminitis.  
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In conclusion, the IT assay for the measurement of TAC was reliable and repeatable, but the ELISAs 
evaluated for the measurement of HMWAC and TAC were not. TAC was significantly lower in 
previously laminitic ponies and in non-laminitic ponies that subsequently developed laminitis in the 
next 12 months. The accuracy of TAC in distinguishing between animals that did and did not develop 
laminitis after 12 months was good and it generated a cut-off value with acceptable sensitivity and 
specificity. However, it should be acknowledged that this cut-off value was generated using samples 
obtained at a single time of year (summer) from ponies kept in a single geographic area and that, as 
no radiography was performed, it is possible that animals with pre-existing subclinical laminitis were 
included. Further prospective cohort studies that examine animals more frequently so that TAC can 
be measured within a shorter period in relation to the onset of laminitis are ongoing to assess this 
risk factor further. 
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Table 1: Mean ± s.d. total adiponectin concentrations in serum, heparinised plasma and EDTA plasma samples collected from 5 horses, stored between -
20°C and 30°C and analysed after 0, 24, 48 and 72 hours storage. Results are expressed as a percentage of the T0 sample that was considered the gold 
standard. Values highlighted in bold were considered unacceptable. 
Storage 
Time 
(Hours) 
-20°C 4°C 23°C 30°C 
Serum Hep 
plasma 
EDTA 
plasma 
Serum Hep 
plasma 
EDTA 
plasma 
Serum Hep 
plasma 
EDTA 
plasma 
Serum Hep 
plasma 
EDTA 
plasma 
0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0 
24 97.4 ± 1.4 98. ± 1.5 99.0 ± 1.5 98.7 ± 2.2 97.3 ± 1.9 95.6 ± 1.6 95.2 ± 0.7 92.3 ± 0.9 86.1 ± 2.2 83.8 ± 3.0 83.8 ± 3.9 77.3 ±3.8 
48 96.6 ± 1.6 95.4 ± 1.4 99.1 ± 2.2 99.4 ± 0.8 98.1 ± 1.1 92.9 ± 3.0 91.7 ± 0.7 90.7 ± 1.0 83.2 ± 1.3 82.1 ± 3.2 81.7 ± 4.5 70.7 ± 4.4 
72 98.9 ± 1.5 98.4 ± 1.8 101.8 ± 2.2 100.2 ± 1.7 99.2 ± 1.7 90.1 ± 3.1 91.6 ±0.5 89.5 ± 1.6 79.7 ± 2.7 81.4 ± 4.0 80.8 ± 5.5 67.9 ± 4.1 
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Figure Legends 
Fig 1: A) Scatter plot of total adiponectin concentration (TAC) measured using immunoturbidimetric 
assay (IT) and radioimmunoassay (RIA) showing linear regression line (red) and B) Bland-Altman plot 
of ratio of TAC measured using IT compared to RIA with mean bias (red line) and limits of agreement 
(blue lines). 
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